Evidence map›Paper›PMID 24144795›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2014

Nitric oxide and interleukin-1β stimulate the proteasome-independent degradation of the retinoic acid hydroxylase CYP2C22 in primary rat hepatocytes.

Choon-myung Lee, Bang-sub Lee, Samuel L Arnold, Nina Isoherranen, Edward T Morgan

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Nitric Oxide Mediated Degradation of CYP2A6 via the Ubiquitin-Proteasome Pathway in Human Hepatoma Cells.Drug metabolism and disposition: the biological fate of chemicals · 2020
    Article
  8. Review
  9. Article
  10. Article
  11. Posttranslational regulation of CYP2J2 by nitric oxide.Free radical biology & medicine · 2018
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Choon-myung LeeDepartment of Pharmacology, Emory University, Atlanta, Georgia (C.-m.L., B.-s.L., E.T.M.); and Department of Pharmaceutics, University of Washington, Seattle, Washington (S.L.A., N.I.).
Bang-sub Lee
Samuel L Arnold
Nina Isoherranen
Edward T Morgan
Emory University · USUniversity of Washington · US

Funding

Regulation of CYP Proteins by Reactive Nitrogen SpeciesR01GM069971 · NIGMS · EMORY UNIVERSITY · PI MORGAN, EDWARD THOMAS · 2004 to 2017
$4.0M
Effects of Xenobiotics on CYP26 Activity and Retinoic Acid HomeostasisR01GM081569 · NIGMS · UNIVERSITY OF WASHINGTON · PI ISOHERRANEN, NINA · 2008 to 2012
$1.7M
NIGMS NIH HHS R01 GM069971NIGMS NIH HHS R01 GM081569
6 · The paper itself

Abstract

CYP2C22 was recently described as a retinoic acid-metabolizing cytochrome P450 enzyme whose transcription is induced by all-trans-retinoic acid (atRA) in hepatoma cells (Qian L, Zolfaghari R, and Ross AC (2010) J Lipid Res 51:1781-1792). We identified CYP2C22 as a putative nitric oxide (NO)-regulated protein in a proteomic screen and raised specific polyclonal antibodies to CYP2C22 to study its protein expression. We found that CYP2C22 is a liver-specific protein that was not significantly induced by activators of the pregnane X receptor, constitutive androstane receptor, or peroxisome proliferator-activated receptor-α, but was downregulated to <25% of control by the aryl hydrocarbon receptor agonist β-naphthoflavone in cultured rat hepatocytes. CYP2C22 protein and its mRNA both were induced by atRA in hepatocytes, with EC50 of 100-300 nM, whereas the maximal extent of mRNA induction was twice that of the protein. CYP2C22 protein, but not its mRNA, was rapidly downregulated in hepatocytes by interleukin-1 (IL-1) or NO-donating compounds, and the downregulation by IL-1 was blocked by inhibition of NO synthases. The NO donor (Z)-1-[N-(3-aminopropyl)-N-(3-ammoniopropyl)amino]diazen-1-ium-1,2-diolate reduced the half-life of CYP2C22 from 8.7 to 3.4 hours in the presence of cycloheximide, demonstrating that NO-dependent downregulation is due to stimulated proteolysis. No intermediate degradation products were detected. However, this degradation was insensitive to inhibitors of calpains or the canonical proteasomal or lysosomal pathways, indicating that NO-dependent degradation of CYP2C22 proceeds via a novel pathway.

Indexed as

Cytochrome P-450 Enzyme InhibitorsAmino Acid SequenceAnimalsCytochrome P-450 Enzyme SystemDown-RegulationHEK293 CellsHepatocytesHumansInterleukin-1betaMaleMixed Function OxygenasesMolecular Sequence DataNitric OxideNitric Oxide DonorsPrimary Cell CultureProteasome Endopeptidase Complexcytochrome P-450 2C22, ratCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemInterleukin-1betaMixed Function OxygenasesNitric OxideNitric Oxide DonorsProteasome Endopeptidase ComplexTretinoin

Identifiers

PMID24144795
PMCPMC3868880
OpenAlexW2106491599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.